Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614378 · ClinicalTrials.gov registry record · NA
Abortive Effect of an Ear Insufflator on Migraine
A NA study, sponsored by Carrick Institute for Graduate Studies.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT02614378: Completed NA study, sponsored by Carrick Institute for Graduate Studies.
NCT02614378 is a NA study that has completed, run by Carrick Institute for Graduate Studies. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02614378, a NA study, has completed, sponsored by Carrick Institute for Graduate Studies.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
Evaluate the effectiveness of air insufflation in aborting (stopping) an acute episode of migraine and compare it with a placebo effect of using the same procedure but without active insufflation. The insufflation will be used when the subject is experiencing an acute episode of migraine to determine its ability to reduce, if not to completely eliminate the migraine symptoms. Subjects receiving the placebo treatment will be offered the active treatment during the subsequent episode of migraine.
Primary Outcome
Subjects will grade the severity of their symptoms on a scale from 0 to 10. Changes in the symptoms severity scale will be assessed between pre and immediately post treatment
Interventions
- PROCEDURE placebo
- PROCEDURE air insufflation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-12 |
| Phase | NA |
What the finished NCT02614378 record still lists
NCT02614378 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02614378 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02614378 about?
NCT02614378 is a clinical study titled "Abortive Effect of an Ear Insufflator on Migraine". Evaluate the effectiveness of air insufflation in aborting (stopping) an acute episode of migraine and compare it with a placebo effect of using the same procedure but without active insufflation. The insufflation will be used when the subject is experiencing an acute episode of migraine to determin...
What is the current status of trial NCT02614378?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2015-11. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02614378?
The interventions under investigation include: placebo (PROCEDURE), air insufflation (PROCEDURE).
Who is sponsoring clinical trial NCT02614378?
This trial is sponsored by Carrick Institute for Graduate Studies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02614378's enrollment target sits among peer trials
58 1256th of 2000 higher than 740 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia